Hypertension, Vascular Rarefaction and Angiopoietin-1 by Bae, Jang-Whan
575
Print ISSN 1738-5520 / On-line ISSN 1738-5555




Correspondence: Jang-Whan Bae, MD, Division of Cardiology, Department of Internal Medicine, College of Medicine, Chungbuk National University, 62 
Gaesin-dong, Heungdeok-gu, Cheongju 361-711, Korea
Tel: 82-43-269-6011, Fax: 82-43-273-3252, E-mail: drcorazon@hanmail.net
• The author has no financial conflicts of interest.
cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licens-
es/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Refer to the page 590-595
Hypertension is a very common but incompletely under-
stood disease, especially in its pathogenesis and vascular com-
plications occurring in the cardiovascular research filed. Th-
ere are many explanations for pathological mechanisms in hy-
pertension, including adrenergic over-reactivity, renin-angio-
tensin-aldosteron system abnormality and constitutional-
genetic-environmental factors. 
Recently emerging evidences support a novel view of hy-
pertension, as a disease of inadequate or abnormal responses 
to angiogenic factors and its related vascular rarefaction and 
remodeling.
1) To date, the best way to prevent or reduce hyper-
tension-related vascular complications is lowering the blood 
pressure (BP). 
However, recent studies have shown that controlling BP 
does not completely prevent cardiovascular or renal compli-
cation in hypertension, indicating that hypertension is one of 
the risk factors in developing cardiovascular complications 
or target organ damages (TODs).
2) 
Therefore, we need more understanding about the vascular 
changes related not just to BP and its control, but also to en-
dothelial dysfunction or vascular remodeling ragarding the 
angiogenic factors in the pathological mechanism and TOD 
process in hypertension.
2) 
The series of articles of Kim et al. showed us the various 
favorable vascular effects of angiopoietin-1 (Ang-1), as an an-
giogenic factor, on vascular rarefaction and target organ dama-
ge in hypertension.
3)4)
Vascular Rarefaction in Hypertension 
Development and Target  
Organ Damage
The connection between microscopic vascular changes and 
angiogenesis is very important in the development and ag-
gravation of hypertension. Underlying TOD resulting from 
hypertension is the functional and structural change in vas-
culature, especially in micro-vessels, which become constrict-
ed, under-perfused, and disappear, during the so-called rar-
efaction. Since the majority of the total vascular resistance oc-
curs in small caliber vessels, i.e., less than 150 µm in diameter, 
vascular rarefaction could contribute to increased vascular 
resistance, TOD, and finally, vascular complications.
5) These 
damages and the disappearance of micro-vessels in hyper-
tension are closely related to endothelial cell (EC) apoptosis 
originated from a variety of vascular stress.
6) Although rar-
efaction could be a consequence of hypertension, there is some 
evidence supporting a primary role for rarefaction in the pro-
cess of hypertension. For example, early skin capillary rarefac-
tion has been shown in normotensive offsprings of hyper-
tensive ancestors.
7) Therefore, there is theoretical room for the 
therapeutic potential of angiogenic factors, especially Ang-1, 
to enhance angiogenesis and microvascular reconstitution 
to reduce both BP and target organ damage in hypertension. 
Angiopoietin-1 and Its Actions  
on Vasculature
The proteins in the angiopoietin (Ang) family, i.e., Ang-1, 
2, 3, and 4 are secreted protein ligands of tyrosinekinase 
with immunoglobulin and epidermal growth factor homolo-
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gy domain 2 (Tie2), and are mainly expressed in the endoth-
elial hematopoietic stem cells and a subset of monocytes and 
macrophages.
8) Ang structure is composed of a carboxy-ter-
minal fibrinogen-like domain, which is mainstay to bind, a 
central coiled-coil domain that oligomerizes the fibrinogen-
like domains, and a short amino-terminal domain that su-
perclusters these oligomers into variably-sized multimers.
8) 
Ang-1 is involved in angiogenesis and induces vascular sta-
bilization by enhancing endothelial integrity; the non-leaky 
and tight vascular network formation is the particular char-
acteristic of Ang-1, compared to vascular endothelial growth 
factor (VEGF).
8) Ang and Tie families have primary roles in 
the late stages of vascular development and adult vasculature, 
where they control remodeling and stabilization of the vessels. 
Thus, Ang-1 is required for correct organization and matu-
ration of newly formed vessels, and promotes the quiescence 
and structural integrity of adult vasculature. Recently, Ang-1 
has been shown to have potent effects on adult vessels, in-
cluding survival promotion, vascular leakage inhibition, and 
inflammatory gene suppression.
9) Very diverse cellular or in 
vivo effects of Ang-1 have been clarified. Firstly, Ang-1 inhib-
its EC apoptosis, and also protects human umbilical vein en-
dothelial cells, aortic and microvascular ECs from apoptosis 
induced by serum deprivation, hyperosmolarity and tumor 
necrosis factor-α.
9) Ang-1 reduces apoptosis in non-EC, e.g., 
mouse cortical neurons and skeletal and cardiac myocytes. 
This anti-apoptosis effect of Ang-1 occurs by activation of 
PI3K/Akt pathway, which is activated in response to Ang-1 
through recruitment of the regulatory p85 subunit of PI3K 
to phosphorylated tyrosine residue 1,102 in the intraceullu-
lar domain of Tie2.
9) In vivo, Ang-1 increased vessel survival 
in studies of radiation-exposed mice, and decreased plasma 
leakage from skin vessels after treatment with inflammatory 
stimuli or VEGF.
10) In addition, Ang-1 has important roles in 
stimulating vascular remodeling, lymphatic proliferation and 
sprouting, and inhibition of leukocyte adhesion, allograft fi-
brosis, and endotoxemia.
9) Ang-2 shows very distinct features 
on angiogenesis, according to tissue environment; thus, Ang-
1 stimulates Tie2 and Ang-2 can antagonize the effect of Ang-
1 on Tie2. However, Ang-2 shows angiogenic activity only 
in the presence of VEGF.
8) 
Angiopoietin-1, Endothelial Nitric  
Oxide Synthase Activation and  
Endothelial Cell Survival  
Enhancement in Hypertension 
Previously, Kim et al. showed that treatment with one gene-
tic variant of Ang-1, i.e., the Cartilage Oligomeric Matrix Pro-
tein-Ang-1 (COMP-Ang-1) plasmid, effectively reduced BP 
and significantly limited microvascular rarefaction and tis-
sue damages in the heart and kidney of the spontaneously hy-
pertensive rat (SHR) model.
3) These effects were completely 
abolished by pre-treatment with adenovirus carrying soluble 
Tie2 receptor, one day before COMP-Ang-1 gene transfer. 
The soluble Tie2 receptor competed with the native Tie2 on 
biding EC with its ligand, and inhibited ligand-induced Tie2 
activation. Tie2 strongly phosphorylated by COMP-Ang-1 
overexpression induced significant endothelial nitric oxide 
synthase (eNOS) production, as a downstream molecule of 
Tie2, and expressed higher amount of NO, compared to 
LacZ-treated SHR. Higher level of NO was confirmed by el-
evated serum level of nitrite, the metabolite of NO. The au-
thors suggested that eNOS overexpression and elevated level 
of NO by COMP-Ang-1 induced reduction of BP, improve-
ment of endothelial dysfunction, enhancement of EC survival 
and limitation of vascular rarefaction in the heart and kid-
ney of SHR. 
The new study of Kim et al. suggested a new potential me-
chanism of COMP-Ang-1 which is not depend on the NO to 
limit vascular rarefaction and reduce BP in SHR.
4) In that 
study, the authors pretreated SHR with a NOS inhibitor, i.e., 
N
W-nitro-L-arginine methyl ester (L-NAME) to exclude NO-
mediated effects in COMP-Ang-1 gene delivery. Even after 
pretreatment with L-NAME, COMP-Ang-1 plasmid deliv-
ery using electrophoretic transfer effectively blocked the de-
velopment of hypertension and attenuated microvascular 
rarefaction and arteriolar remodeling in the heart and kidney 
of SHR, compared to LacZ plasmid delivery control. The 
number of capillaries in the heart and kidney, counted by en-
dothelial specific CD31 or RecA antibody staining, was sig-
nificantly higher in the COMP-Ang-1 group in NOS-inhibit-
ed SHR, compared to LacZ-transferred SHR control. Myo-
cardial fibrosis, glomerular fibrinoid necrosis and tubular 
interstitial fibrosis were also less observed in the COMP-
Ang-1 group in NOS-inhibited SHR. What is the main mo-
lecular mechanism to reduce BP and limit vascular rarefac-
tion of COMP-Ang-1 in L-NAME pretreated SHR? Although 
there are no confirmatory experiments in the study of Kim 
et al. we can suggest the anti-fibrotic and anti-inflammatory 
effects of Ang-1 as possible explanations. Similarly, the PI3 
kinase/Akt pathway activation by COMP-Ang-1 to limit EC 
apoptosis and to enhance cellular survival can be a molecu-
lar mechanism to reduce rarefaction, vascular structural ab-
normality and BP elevation in L-NAME pretreated SHR. 
Further studies will be necessary to determine the molecular 
pathways of Ang-1 to limit vascular complications in NOS-
inhibited SHR. This will give us important information to ap-
ply Ang-1 at clinical level, as a potential antihypertensive drug. 
Potential Clinical Applications of Ang1
The in vivo effects of Ang-1 suggest that manipulation of 
this ligand may have therapeutic potential in some clinical ap-Jang-Whan Bae   577
plications, Because Ang-1 delivery shows rapid revascular-
ization, EC apoptosis reduction, tight and non-leaky vascular 
network formation and blood pressure reduction, Ang-1 has 
potential indication in diabetic retinopathy, allograft vascu-
lopathy, sepsis/endotoxemia and stroke.
9) Blocking the anti-
body for Ang-1 can also be used in malignancy.
9) Concurrent-
ly, up to 20 early phase clinical trials related to Ang are either 
ongoing or terminated, and most studies are focused on ad-
vanced solid tumor (from clinicaltrials.org). Is there any pos-
sibility to use Ang-1 as a potential anti-hypertensive drug in 
the future? More detailed and fine in vitro experiments and 
preclinical models to determine the molecular pathways to ad-
just blood pressure, vascular complications, and potential ad-
verse reactions of Ang-1 should be performed in the near fu-
ture, providing confirmation of Ang-1 effects in vascular rare-
faction and hypertension.
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